Sign In
Buy MESO
$14.52
+0 (+0%)
At Close: Jun 03, 2026
Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024
07:27pm, Wednesday, 28'th Aug 2024
NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and
Mesoblast Financial Results and Corporate Update Webcast
07:25pm, Tuesday, 27'th Aug 2024
NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operation
Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024
09:13pm, Tuesday, 30'th Jul 2024
Ryoncil BLA Submission Under FDA Review for Approval in Children with SR-aGVHD Ryoncil BLA Submission Under FDA Review for Approval in Children with SR-aGVHD
If Approved, RYONCIL will be the First Allogeneic “Off-the-Shelf” Cellular Medicine in the US, and the First Cell Therapy for Children Up To 18 Years Old with SR-aGVHD If Approved, RYONCIL will be
Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain
08:45pm, Sunday, 21'st Jul 2024
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Ph
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today it has resubmitted its B
Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates
09:40am, Tuesday, 02'nd Jul 2024
Mesoblast (MESO) skyrockets 208.2% year to date on encouraging progress with its pipeline candidates.
Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week
01:55am, Monday, 01'st Jul 2024
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its Bi
Mesoblast Corporate Presentation at Investor Conference
08:23pm, Sunday, 02'nd Jun 2024
NEW YORK, June 02, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), Chief Executive Silviu Itescu provided a corporate update at the Bell Potter Emerging Leaders Conference.
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024
09:05pm, Monday, 29'th Apr 2024
FDA Provides Clarity on Path to Licensure for Remestemcel-L in SR-aGVHD and Rexlemestrocel-L in End-Stage Heart Failure FDA Provides Clarity on Path to Licensure for Remestemcel-L in SR-aGVHD and Rexl
Feeling Bold? 3 Aggressive Plays to 10X Your Returns by 2025
07:00am, Wednesday, 03'rd Apr 2024
For bold investors, there are few opportunities as exciting as chasing 10x returns in the stock market. Make no mistake about it, the stock market offers up multiple opportunities to turn $1 into $10
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
12:01pm, Wednesday, 27'th Mar 2024
Mesoblast (MESO) gains as the FDA states that the available phase III data for lead candidate, remestemcel-L, is sufficient to support a regulatory filing for pediatric SR-aGVHD indication.
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA has infor
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
07:30pm, Wednesday, 13'th Mar 2024
NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received firm co
NEW YORK, March 10, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA supports
